



Gamma Vaccines Changes its Status to a Public Company Limited by Shares

Adelaide, Australia, 18 March 2025 – Gamma Vaccines announces that it has changed its status from a Private Company limited by shares to a Public Company limited by shares and changed its name to Gamma Vaccines Ltd.

Shareholders at the Company’s Annual General Meeting held on Tuesday 6th February 2025 voted unanimously to change the status of the company from a proprietary limited (private) company to a limited (public unlisted) company, in accordance with Section 162 of the Corporations Act.

This decision was taken because of the strong interest from Australian and overseas sophisticated investors to participate in the Company’s Series A1 capital raising round. Section 113 of the Corporations Act provides that a proprietary limited Company must have no more than 50 non-employee shareholders if it is to remain registered as a proprietary company. In anticipation that the number of non-employee shareholders in the Company was likely to exceed 50 non-employee shareholders upon completion of the Series A1 round, Shareholder approval was sought for the Company to change its status from a proprietary company limited by shares to a public company limited by shares and approval for the consequential changes to the Company’s name and Constitution.

The Company was incorporated as "Gamma Vaccines Pty Ltd" in July 2009. With effect from today’s date the Company’s name will be "Gamma Vaccines Ltd".

As a public company, Gamma Vaccines will be subject to more onerous regulation pursuant to the Corporations Act, including increased disclosure and reporting obligations. The company will also be subject to the related party provisions of the Corporations Act which require shareholder approval for the provision of a financial benefit to related parties of the company.

Gamma Vaccines’ Chairman, **Adjunct Professor Tim Hirst** commented, “This is an important milestone in the corporate development of Gamma Vaccines and reflects growing interest in the Company from both Australian and international investors” He noted that “Gamma Vaccines has always upheld the importance of financial reporting and shareholder disclosure and that the changed status of the Company simply enshrines obligations, to which we were already committed.”

About Gamma Vaccines

Gamma Vaccines is a public (unlisted) biotechnology company established to solve one of the great challenges in infectious disease - the development of a “universal” cross-protective influenza virus vaccine. The company’s technology can create highly effective “whole virus” vaccines that elicit a maximum breadth of protective immune responses to influenza viruses. In addition, Gamma Vaccines has a pipeline of vaccine opportunities aimed at preventing other globally important viral diseases of humans, including against Chikungunya, a mosquito-borne virus that causes frequent outbreaks of debilitating arthritic disease. The company also expects its technology will offer near market opportunities for veterinary applications, including avian influenza (AI) and Newcastle Disease Virus (NDV) vaccines for preventing bird flu and NDV outbreaks in poultry.